Skip to main content

Menu

BNF June 2022 Update

This update contains 8 significant changes, 3 dose changes, 1 new monograph, and 2 new preparations.

Significant Changes:

  • Colecalciferol [maximum daily dose added for treatment of vitamin D deficiency].
  • Ear: updated guidance for the management of acute otitis media.
  • Ergocalciferol [maximum daily dose added for treatment of vitamin D deficiency].
  • Esketamine (Spravato®): new requirement to register patients onto Spravato® Register and Alert system.
  • Human papillomavirus vaccine: updated guidance in-line with UK Health Security Agency recommendations.
  • Immunisation schedule: updated guidance for immunisation against human papillomavirus and influenza.
  • Influenza vaccine: updated guidance in-line with UK Health Security Agency recommendations.
  • Pregabalin (Lyrica®): findings of safety study on risks during pregnancy [MHRA/CHM advice].

Dose Changes:

  • Erythromycin [amended age range for otitis media and sore throat in children].
  • Human papillomavirus vaccines [update to indications and dosing].
  • Isavuconazole [addition of dose equivalence and conversion statement].

New Monographs:

  • Givlaari® [givosiran].

New Preparations:

  • Xaqua® [metolazone].
  • Zubsolv® [buprenorphine with naloxone].

For further details on changes in the BNF click on https://www.medicinescomplete.com/#/content/bnf/PHP107699